Audentes Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, June 28, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its participation in the following upcoming investor conferences:

• Piper Jaffray GenomeRx Symposium
  Panel: Gene Therapy – Tackling Manufacturing
  July 11, 2017, 11:20 am ET
  The Lotte New York Palace, New York
  
• Wedbush PacGrow Healthcare Conference
  Corporate Presentation
  August 15, 2017, 12:45 pm ET
  Le Parker Meridien Hotel, New York

To access a live webcast of the corporate presentation at the Wedbush PacGrow Healthcare Conference, please visit the Events & Presentations page within the Investors & News section of the Audentes website. A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference. There is no webcast available for the Gene Therapy – Tackling Manufacturing panel at the Piper Jaffray GenomeRx Symposium.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Thomas Soloway, CFO
415.818.1040
[email protected]

Media Contact:
Paul Laland
415.519.6610
[email protected]

SOURCE Audentes Therapeutics, Inc.

Related Links

http://www.audentestx.com